Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis

US10933038B2 · kind B2 · utility

Assignees

• Hebei Medfaith Pharmaceutical Technology Co., Ltd. · CN
• Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences · CN

Inventors

• Hongwei Tian · Beijing, CN
• Xingang Wang · Tangxia, CN
• Rongguang Shao · Beijing, CN
• Yucheng Wang · Qingdao, CN
• Naren Li · Beijing, CN
• Shi-Ying Cai · Cheshire, US
• Hongwei He · Beijing, CN
• Juxian Wang · Beijing, CN
• Shuangshuang Zhao · Suzhou, CN
• Maoxu Ge · Beijing, CN
• Jinfeng Ren · Beijing, CN

Key dates

• Filing date: Nov 24, 2016
• Grant date: Mar 2, 2021
• Expiry date: Nov 24, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.